Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen del Rocío (26)

2024

  1. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

    eClinicalMedicine, Vol. 71

  2. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

    Infection

  3. Ponalfil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Long-term results

    HemaSphere

  4. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry

    Hematological Oncology, Vol. 42, Núm. 1

2023

  1. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings

    International Journal of Infectious Diseases, Vol. 137, pp. 98-110

  2. Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group

    Blood Cancer Journal, Vol. 13, Núm. 1

  3. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey

    Blood Advances, Vol. 7, Núm. 11, pp. 2645-2655

  4. Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry

    Cancers, Vol. 15, Núm. 2

2022

  1. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

    Blood cancer journal, Vol. 12, Núm. 4, pp. 68

  2. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

    Blood, Vol. 140, Núm. 26, pp. 2773-2787

  3. COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP

    Blood Advances, Vol. 6, Núm. 7, pp. 2427-2433

  4. Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 11, pp. 1196-1205

  5. Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study

    Cancers, Vol. 14, Núm. 23

  6. Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia

    Blood Advances, Vol. 6, Núm. 18, pp. 5395-5402

  7. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients

    Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550

2021

  1. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma

    Blood, Vol. 137, Núm. 1, pp. 49-60

  2. Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group

    British Journal of Haematology, Vol. 192, Núm. 3, pp. 522-530

2020

  1. A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

    European Journal of Haematology, Vol. 104, Núm. 5, pp. 435-442

  2. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792

  3. Pembrolizumab as consolidation strategy in patients with multiple myeloma: Results of the GEM-pembresid clinical trial

    Cancers, Vol. 12, Núm. 12, pp. 1-13